PARTHSARTHI PATEL: Open Payments
NPI 1629171756 · NEWINGTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,938 in 167 payments from 26 companies in 2025. Trend: 2023 $2,857 · 2024 $2,897 · 2025 $2,938
Food & beverage: $2,938
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $571 |
| ABBVIE INC. | 35 | $531 |
| GlaxoSmithKline, LLC. | 14 | $202 |
| Bayer Healthcare Pharmaceuticals Inc. | 18 | $189 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $171 |
| Esperion Therapeutics, Inc. | 11 | $151 |
| Lilly USA, LLC | 5 | $134 |
| Vanda Pharmaceuticals Inc. | 4 | $116 |
| PFIZER INC. | 5 | $103 |
| Indivior Inc. | 3 | $88 |
Products named: BREZTRI, TRELEGY ELLIPTA, VRAYLAR, Kerendia, CAPLYTA, QULIPTA, NEXLETOL, HETLIOZ.
Industry payments across CT — which companies pay providers there.
